



Received on 08 March 2014; received in revised form, 20 May 2014; accepted, 26 June 2014; published 01 September 2014

## ANOVULATORY FOLLICLE DEVELOPMENT IN ADULT ALBINO MICE DUE TO PROLONGED EXPOSURES TO GENISTEIN

S. Banik <sup>1</sup>, A. D. Banik <sup>\*2</sup> and V. K. Shrivastava <sup>2</sup>

Department of Zoology <sup>1</sup>, Regional Institute of Education, NCERT, Bhopal - 462013, Madhya Pradesh, India.

Laboratory of Endocrinology <sup>2</sup>, Department of Bioscience, Barkatullah University, Bhopal - 462026, Madhya Pradesh, India.

### Keywords:

Phytoestrogen, Genistein,  
Folliculogenesis, Gonadotropins,  
Estrogen

### Correspondence to Author: Arunima Datta Banik

Senior Research Fellow,  
Laboratory of Endocrinology,  
Department of Bioscience,  
Barkatullah University, Bhopal -  
462026, Madhya Pradesh, India.

**E-mail:** arunimadattabanik@gmail.com

**ABSTRACT:** Genistein is a soy phytoestrogen that mediates its functions by interacting with the endogenous estrogen receptor  $\beta$ . To investigate the effect of 10mg/kg body weight/ day genistein administration up to 90 days on the ovarian folliculogenesis and its correlation with serum gonadotropins and estrogen, adult *Mus musculus* were either administered with 1:4 DMSO : PBS (vehicle) or with 10mg genistein/kg body weight dissolved in vehicle for 30, 60 and 90 days. Post sacrifice on 31<sup>st</sup>, 61<sup>st</sup> and 91<sup>st</sup> day, blood serum was separated, and the gonadotropins (LH and FSH) and estrogen hormone were estimated by ELISA and Bouin's fixed ovaries of control and treated mice were used for histology after H&E staining. Comparison of the ovarian sections revealed an increased number of arrested anovulatory follicles along with the treatment groups, i.e., 30 60 and 90 days and chronological decrease in the serum concentrations of LH, FSH as well as estrogens (two way ANOVA, at  $p < 0.05$  to  $p < 0.001$ ). Together these results suggested for delayed folliculogenesis, and reduced number of mature oocytes, which could be correlated with less to nil offspring production signifying lesser fertility or sometimes severity may end up in sterility.

**INTRODUCTION:** It is well documented that during the normal process of ovarian differentiation, the germ cells form clusters or nests, which have similarities with the germline cysts found in female invertebrates and males of almost all species of animals <sup>1, 2</sup>. These cysts are formed as a result of a series of incomplete cell divisions of the oogonia just after their formation.

These cells remain connected with each other and subsequently undergo meiotic divisions where after they are called oocytes <sup>1</sup>. These germ-line cysts or oocyte nests of mouse dissociate postpartum and become surrounded with pre-granulosa cells to form individual primordial follicles <sup>3</sup>. The dissociation of the germline cysts is known as nest breakdown, during which 2/3<sup>rd</sup> of the total number of oocytes disintegrates, and only 1/3<sup>rd</sup> of them survive <sup>3</sup>.

These events eventually give rise to two subpopulations of oocytes-one being those which survive, differentiate, and form the functional oocytes and the other that support and protect the oocytes but eventually die during the process.

<p><b>QUICK RESPONSE CODE</b></p>	<p><b>DOI:</b> 10.13040/IJPSR.0975-8232.5(9).3752-57</p> <p>This article can be accessed online on <a href="http://www.ijpsr.com">www.ijpsr.com</a></p>
<p>DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.5(9).3752-57">http://dx.doi.org/10.13040/IJPSR.0975-8232.5(9).3752-57</a></p>	

Estrogens have been reported to be involved in the regulation of the programmed cell death and survival of the oocyte sub-populations<sup>4, 5, 6</sup>. It is reported that FSH inhibits follicular atresia and a higher concentration of estrogen inhibits secretion of FSH and is also responsible for atresia<sup>7</sup>. However, estrogens have been shown to protect granulosa cells from undergoing atresia<sup>8</sup>. In contrast to these, there are evidence that estrogens promote cell death in organ systems like nervous system<sup>9</sup>. Whether estrogen treatment regulates the number of degenerative oocytes during nest breakdown is not well established.

Over the years, estrogen and their analogs have been shown to induce various effects on the reproductive system like an abnormality in tissue morphology as well as neoplasia. Most conspicuous of them is the formation of multi-oocyte follicles (MOFs) in the ovaries of adult animals<sup>10</sup>. Neonates treated with either endogenous estradiol 17 $\beta$  (E<sub>2</sub>) or its synthetic analogs (like Diethylstilbestrol/DES) show an increased incidence of developing MOFs during adulthood as compared to the normal ovaries<sup>11, 12, 13</sup>. In spite of these reports, the origin of MOFs remains a mystery. There are many plausible explanations available like, treatment with E<sub>2</sub> during neonatal ovarian differentiation results in the formation of oocyte nests that persists and do not undergo breakdown. Later on, these nests become surrounded by granulosa cells and results in the formation of follicles with more than one oocyte (MOFs) in adult ovary. Another reasonable argument may be that nest breakdown may occur, but the migration of the granulosa cells around the oocyte may get affected. It may also be the case where two or more follicles may fuse to form one follicle. In an argument, if estrogen is the causative factor behind the formation of MOFs, then chemicals with estrogenic properties should also entail for similar kind of effects.

Genistein is soy-derived isoflavonoid compound shown to possess estrogenic activities both *in-vitro* as well as *in-vivo* through its ability to bind to the estrogen receptor  $\beta$ <sup>14</sup>, hence known as a phytoestrogen. Numerous studies have been carried out on mouse and rat models that evidence for the adverse reproductive outcomes of genistein on female systems post administration<sup>15, 16, 17, 18, 19</sup>.

Some of these soy-based edible products have been reported to have high concentrations of genistein. Soy-based infant formulations consume approximately 6–9 mg/kg per day of genistein compared to 1 mg/kg per day in an adult vegetarian diet<sup>20</sup>. Studies also report that neonatal exposure to genistein at a dose of 50mg/kg body weight/day (during postnatal day 1-5) leads to an increased incidence of uterine adenocarcinoma (35%) during adulthood; in comparison to 0.001mg/kg body weight/ day DES-treated animals (31%)<sup>21</sup>. Studies have reported that exposure to genistein during prenatal developmental stages may cause altered reproductive cyclicality, ovarian function as well as subfertility and infertility in adult rodents<sup>22, 23, 24</sup>.

However, a sufficient number of studies has not been carried out regarding the effects of genistein administration in adult mice. Since soy and soy-based edible products and formulations are most widely used in preparations of the vegetarian style diets in India. The study aims to determine the effects of genistein at a dose of 10 mg/kg body weight/day (dissolved in 1:4 DMSO: PBS) up to 90 days, on the histomorphology of the ovary and also to correlate the alterations produced with the changes in the circulating levels of gonadotropins (LH and FSH).

**MATERIALS AND METHODS:** Approximately 7-8 week old thirty female albino mice were housed and acclimated at approximately 24  $\pm$  2 °C temperature with 10 h : 14 h light : dark cycle in the animal house of the Laboratory of Endocrinology, at the Department of Bioscience, Barkatullah University, Bhopal, Madhya Pradesh, India following the guidelines of the Institutional Animal Ethics Committee (IAEC) formed under CPCSEA, Govt. of India. They were provided commercially available mice feed and water *ad libitum*.

Commercially available 98% pure HPLC grade Genistein powder purchased from Sigma Aldrich was used to prepare a dose containing 10 mg Genistein/kg body weight/day, dissolved in 1: 4 Dimethyl sulfoxide (DMSO): Phosphate buffered saline (PBS).

Fifteen females were administered orally 10 mg Genistein/kg body weight/day, dissolved in 1: 4

Dimethyl sulfoxide (DMSO): Phosphate buffered saline (PBS) up to 90 days and remaining fifteen received an equal volume of vehicle (1: 4, DMSO: PBS) alone for 90 days.


On 31<sup>st</sup>, 61<sup>st</sup> and 91<sup>st</sup> day five mice were sacrificed by cervical dislocation, and their blood were collected into sterile collection vials by cardiac puncture method. Sera were separated by appropriate technique and estimation of Luteinizing hormone (LH), Follicle stimulating hormone (FSH) and Estrogen (E<sub>2</sub>) hormone were done using appropriate ELISA assay kits developed by My Bio-Source, Inc., San Diego, USA.

Two-way ANOVA analyses<sup>25</sup> were performed to compare and assess any / at all differences (at  $p < 0.05$  to  $p < 0.001$ ) in the serum LH, FSH and E<sub>2</sub> hormone concentrations obtained from the control and experimental groups after different intervals.

Bouin's fixed ovaries of control and genistein-treated animals were used to prepare 5-7  $\mu$  (micron) sections and stained following standard H&E method<sup>26</sup>. Photomicrography was done at 100X and 400X magnifications with the help of a photomicrography unit (Motic-DMB1-B microscope, fitted with a digital camera).


**RESULTS:** The results show that there had been a chronological decrease in the LH, FSH as well as

Estrogen concentrations. Concentrations of LH decreased significantly ( $p < 0.01$ , via two way ANOVA analysis) after 30, 60, and 90 days of genistein administration **Fig. 1**.



**FIG. 1: COMPARISON OF CIRCULATING LUTEINIZING HORMONE (LH) LEVEL (mIU/ml), WITHIN CONTROL AND GENISTEIN, TREATED FEMALE *MUS MUSCULUS*, AFTER 30, 60 AND 90 DAYS**


The decrease in serum FSH concentration was not significant after 30 days of treatment but significantly decreased ( $p < 0.05$ , via two way ANOVA analysis) sequentially after 60 and 90 days genistein treatment **Fig. 2**. There was significant ( $p < 0.05$ , via two way ANOVA analysis) chronological decrease in the circulatory level of estrogen in comparison to the vehicle-treated control animals **Fig. 3**.



**FIG. 2: COMPARISON OF CIRCULATING FOLLICLE STIMULATING HORMONE (FSH) LEVEL (MIU/ML), WITHIN CONTROL AND GENISTEIN, TREATED FEMALE *MUS MUSCULUS*, AFTER 30, 60 AND 90 DAYS**

Values are expressed in Mean  $\pm$  SEM. Significance of difference:  $p < 0.05$  to 0.001-Two way ANOVA (\*=  $p < 0.05$  & \*\*=  $p < 0.01$  NS= Not Significant)

Histopathological observations of the H-E stained ovaries under 100X, as well as 400X magnifications, revealed a chronological increase in the number of follicles along the 30, 60 and 90



**FIG. 3: COMPARISON OF CIRCULATING ESTROGEN HORMONE (E<sub>2</sub>) LEVEL (NG/ML), WITHIN CONTROL AND GENISTEIN, TREATED FEMALE *MUS MUSCULUS*, AFTER 30, 60 AND 90 DAYS**


days genistein treated animals. H-E stained longitudinal sections (LS) of the control ovary shows different follicular developmental stages scattered through the medullar region of the ovary.

The mature follicles lined around the periphery. The germinal epithelium (GE) is properly organized. Primary, as well as secondary follicles, were prominent. The oocyte is located in a mound of cumulus oophorus (CO) or granulosa cells that are normal in appearance. One developing antrum/follicular cavity is visible. The membrane granulosa (MG) is also persistent (**Fig. 4A & B**).

**Fig. 4C and D** depict the ovarian histology of 30 days genistein treated female. The LS shows the cortex as well as the medullary region that is filled with lesser number of developing follicles but more atretic follicles. Proper MG is seen. The follicles are filled with granulosa cells, and oocytes are missing. Numerous GC filled follicles are visible. One primary follicle is seen, but that is within the periphery of the two follicles.

**Fig. 4E and F** show the ovarian histology after 60 days of genistein administration to female mice. A growing number of follicles filled with GC and less Number of mature follicles are evident. Some arrested follicles at their second stage of maturation are seen. Proper MG and GC are evident.

**Fig. 4G and H** show the ovarian histology after 90 days of genistein administration to female mice. Closely packed anovulatory/arrested follicles filled with GC are seen. Distorted GE is seen. Although primary follicles are present, their numbers are few. Large GC filled follicles are evident.



**FIG. 4: LONGITUDINAL SECTION OF CONTROL AND 30, 60 AND 90 DAYS GENISTEIN TREATED OVARY OF MICE, *MUS MUSCULUS***

**DISCUSSION:** In the current study, we tried to evaluate the effects of genistein exposure on the mature mouse ovary and the circulating levels of the gonadotropins (LH & FSH) and estrogen hormone. Several studies done earlier have shown that neonatal exposure to the soy phytoestrogen genistein alters ovarian morphology later in life, including the presence of MOFs<sup>27</sup>. There may be several possible ways by which such abnormalities may occur. Like, the granulosa cells could improperly enclose more than one oocyte, disruption in the process of oocyte nest breakdown or, a fusion of more than two follicles. Although various reports of MOF formation during neonatal genistein exposure have been reported, there are no such reports on the mature adult ovary.

Development of the ovarian follicles is a complex process involving endocrine, paracrine as well as autocrine regulations. The follicular developmental stages are primordial, secondary, and pre-antral. The mature follicles after that either undergo atresia or under the control of cyclical gonadotropin stimulations they reach pre-ovulatory antral stage followed by the release of an ovum (ovulation) under the influence of estrogen<sup>28</sup>. Folliculogenesis involves interactions between different ovarian cell types, and these cells are triggered by the gonadotropins- FSH and LH. These hormones control the production of ovarian steroids wherein, LH stimulates the internal theca cells to produce aromatizable androgens<sup>29, 30</sup>. The granulosa cells are induced to produce *P*-450<sub>aromatase</sub> (CYP19) under the influence of FSH, which then converts the androgens into estrogens in these cells<sup>29, 30, 31</sup>.

This study shows that there had been a significant drop in the levels of gonadotropins as well as estrogen. Researchers have shown that estrogens protect the granulosa cells from undergoing apoptosis, whereas the androgens enhance GC apoptosis<sup>32</sup>. Therefore, it is possible that the growing concentration of estrogen has protected the developing cells from undergoing apoptosis and therefore reduction in the number of maturing follicles and increase in atresia. The increased concentration of estrogen signals the pituitary to stop the synthesis of FSH and LH; therefore, in turn, blocks folliculogenesis. To the contrary, genistein is an estrogen mimic that also mediates its

functions interacting with the estrogen receptor  $\beta$ , and that may have caused the increase in the number of GC filled follicles in adult ovary. Unlike neonatal treatment with genistein that causes MOF formation in the ovaries, prolonged treatment (up to 90 days) with genistein causes the formation of GC filled follicles. Although, less amount of endogenous estrogen may be available, the block in apoptosis may have been served by genistein.

In one study in rats, neonatal progesterone treatment has been found to reduce primordial follicle assembly in contrast to both progesterone and estrogen treatment, which reduced the transition from primordial to the primary follicle in the initial steps of folliculogenesis<sup>33</sup>. However, oocyte nest breakdown was not specifically examined; this study also showed reduced neonatal oocyte apoptosis in progesterone-treated mice. Together these data suggested that the steroid hormone balance may also be important for proper ovarian differentiation and development. Research on phytoestrogens, like genistein, has increased over the last decade. There are certain contradictory results that have been put forward to the scientific community regarding the benefits as well as adverse effects of genistein in a dose and duration-dependent manner. Some studies have shown that exposure to genistein during early developmental periods prevents carcinogen-induced mammary gland cancer<sup>34, 35</sup>, while others have reported the increased occurrence of mammary gland cancer following treatment during specific developmental windows<sup>36</sup>. It has been reported that genistein improves cholesterol synthesis rates of human infants consuming soy-based formulas<sup>37</sup>.

Vegetarian diets usually contain high levels of soy, and recent epidemiology reports have shown an association of a vegetarian diet during pregnancy with an increased incidence of hypospadias in the male offspring<sup>38</sup>. Correlations have also been found between the increase in autoimmune disease and the use of allergy medicines in children fed soy-based infant formulas<sup>39</sup>. Not only genistein but neonatal exposure to different environmental estrogen such as bisphenol A has also been shown to cause MOFs in mice<sup>40</sup>. This finding further supports the idea that the estrogenic activity of any exogenous substance may cause altered ovarian differentiation.

**CONCLUSION:** it can be proposed that ovarian differentiation is a complex and multifaceted process; in which, disruption in any of the pathways can lead to alterations in the normal progression of ovarian development and subsequent normal ovarian function. Therefore unlike neonatal exposure to genistein that causes early differentiation defects in folliculogenesis; genistein exposure at a dose of 10 mg/kg body weight/day up to 90 days, during adulthood causes reduced atresia, development of GC rich anovulatory follicles as well as a block during secondary follicular growth and differentiation, which are signs of reproductive malfunctioning in female subjects exposed to genistein.

**ACKNOWLEDGEMENT:** The authors are thankful to Madhya Pradesh Council of Science and Technology, Bhopal, India, for financial support.

**CONFLICT OF INTEREST:** Nil

#### REFERENCES:

1. Pepling ME and Spradling AC: Female mouse germ cells form synchronously dividing cysts. *Development* 1998; 125(17): 3323-28.
2. Pepling ME, de Cuevas M and Spradling AC: Germline cysts: a conserved phase of germ cell development. *Trends Cell Biol* 1999; 9(7): 257-62.
3. Pepling ME and Spradling AC: Mouse ovarian germ cell cysts undergo programmed breakdown to form primordial follicles. *Dev Biol* 2001; 234(2): 339-51.
4. Perillo B, Sasso A, Abbondanza C and Palumbo G: 17 beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression *via* two estrogen responsive elements present in the coding sequence. *Mol Cell Biol* 2000; 20(8): 2890-01.
5. Razandi M, Pedram A and Levin ER: Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. *Mol Endocrinol* 2000; 14(9): 1434-47.
6. Singer CA, Rogers KL, Strickland TM and Dorsa DM: Estrogen protects primary cortical neurons from glutamate toxicity. *Neurosci Lett* 1996; 212(1): 13-16.
7. Kaipia A and Hsueh AJ: Regulation of ovarian follicle atresia. *Annual review of physiology* 1997; 59(1):349-363.
8. Billig H, Furuta I and Hsueh AJ: Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. *Endocrinology* 1993; 133(5): 2204-12.
9. Zhang L, Li B, Zhao W, Chang YH, Ma W, Dragan M, Barker JL, Hu Q and Rubinow DR: Sex-related differences in MAPKs activation in rat astrocytes: effects of estrogen on cell death. *Brain Res Mol Brain Res* 2002; 103(1-2): 1-11.
10. Iguchi T, Watanabe H and Katsu Y: Developmental effects of estrogenic agents on mice, fish, and frogs: a mini-review. *Horm Behav* 2001; 40(2): 248-51.
11. Iguchi T, Fukazawa Y, Uesugi Y and Takasugi N: Polyovular follicles in mouse ovaries exposed neonatally

- to diethylstilbestrol *in-vivo* and *in-vitro*. Biol Reprod 1990; 43(3): 478-84.
12. Iguchi T and Takasugi N: Polyovular follicles in the ovary of immature mice exposed prenatally to diethylstilbestrol. Anat Embryol (Berl) 1986; 175(1): 53-55.
  13. Iguchi T, Takasugi N, Bern HA and Mills KT: Frequent occurrence of polyovular follicles in ovaries of mice exposed neonatally to diethylstilbestrol. Teratology 1986; 34(1): 29-35.
  14. Kim H, Peterson TG and Barnes S: Mechanisms of action of the soy isoflavone genistein: an emerging role for its effects *via* transforming growth factor  $\beta$  signaling pathways. Am J Clin Nutr. 1998; 68(6S): 1418S-25S.
  15. Diel P, Smolnikar K, Schulz T, Laudenschlager U, Michna H and Vollmer G: Phytoestrogens and carcinogenesis-differential effects of genistein in experimental models of normal and malignant rat endometrium. Hum Reprod 2001; 16(5): 997-06.
  16. Jefferson WN, Padilla-Banks E, Clark G and Newbold RR: Assessing estrogenic activity of phytochemicals using transcriptional activation and immature mouse uterotrophic responses. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 777(1-2): 179-89.
  17. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B and Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endo 1998; 139(10): 4252-63.
  18. Milligan SR, Balasubramanian AV and Kalita JC: Relative potency of xenobiotic estrogens in an acute *in-vivo* mammalian assay. Env Health Persp 1998; 106(1): 23-26.
  19. Whitten PL, Russell E and Naftolin F: Effects of a normal, human concentration, phytoestrogen diet on rat uterine growth. Steroids 1992; 57(3): 98-06.
  20. Setchell KD, Zimmer-Nechemias L, Cai J and Heubi JE: Exposure of infants to phytoestrogens from soy-based infant formula. Lancet 1997; 350(9070): 23-27.
  21. Jefferson WN, Padilla-Banks E and Newbold RR: Adverse effects on female development and reproduction in CD-1 mice following neonatal exposure to the phytoestrogen genistein at environmentally relevant doses. Biol Reprod 2005; 73(4): 798-06.
  22. Kouki T, Kishitake M, Okamoto M, Oosuka I, Takebe M and Yamanouchi K: Effects of neonatal treatment with phytoestrogens, genistein and daidzein, on sex difference in female rat brain function: estrous cycle and lordosis. Horm Behav 2003; 44(2): 140-45.
  23. Levy JR, Faber KA, Ayyash L and Hughes CL: The effect of prenatal exposure to the phytoestrogen genistein on sexual differentiation in rats. Proc Soc Exp Biol Med 1995; 208(1): 60-66.
  24. Nikaïdo Y, Yoshizawa K, Danbara N, Tsujita-Kyutoku M, Yuri T, Uehara N and Tsubura A: Effects of maternal xenoestrogen exposure on the development of the reproductive tract and mammary gland in female CD-1 mouse offspring. Reprod Toxicol 2004; 18(6): 803-11.
  25. Zar JH: Biostatistical Analysis. India: Pearson Education, Edition 4, 2008, 231-72.
  26. Lillie RD and Fullmer HM: Histopathologic technique and practical histochemistry. New York: Mc. Graw Hill Books Co., Edition 4, 1976: 24-80.
  27. Jefferson WN, Couse JF, Padilla-Banks E, Korach KS and Newbold RR: Neonatal exposure to genistein induces estrogen receptor (ER) alpha expression and multi-oocyte follicles in the maturing mouse ovary: evidence for ER-beta-mediated and nonestrogenic actions. Biol Reprod 2002; 67(4): 1285-96.
  28. Gougeon A: Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996; 17(2): 121-55.
  29. Hillier SG, Whitelaw PF and Smyth CD: Follicular estrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited. Mol Cell Endocrinol 1994; 100(1-2): 51-54.
  30. Karnitis VJ, Townson DH, Friedman CI and Danforth DR: Recombinant human follicle-stimulating hormone stimulates multiple follicular growth, but minimal estrogen production in gonadotropin-releasing hormone antagonist-treated monkeys: examining the role of luteinizing hormone in follicular development and steroidogenesis. J Clin Endocrinol Metab 1994; 79(1): 91-97.
  31. Smyth CD, Miro F, Howles CM and Hillier SG: Effect of luteinizing hormone on follicle stimulating hormone-activated paracrine signaling in rat ovary. Hum Reprod 1995; 10(1): 33-39.
  32. Billig H, Furut I and Hsueh AJ: Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 1993; 133(5): 2204-12.
  33. Kezele P and Skinner MK: Regulation of ovarian primordial follicle assembly and development by estrogen and progesterone: an endocrine model of follicle assembly. Endocrinology 2003; 144(8): 3329-37.
  34. Hilakivi-Clarke L, Onojafe I, Raygada M, Cho E, Skaar T, Russo I and Clarke R: Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer 1999; 80(11): 1682-88.
  35. Lamartiniere CA, Zhang JX and Cotroneo MS: Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr 1998; 68(6): 1400S-1405S.
  36. Hilakivi-Clarke L, Cho E, Onojafe I, Raygada M and Clarke R: Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep 1999; 6(5): 1089-95.
  37. Cruz ML, Wong WW, Mimouni F, Hachey DL, Setchell KD, Klein PD and Tsang RC: Effects of infant nutrition on cholesterol synthesis rates. Pedia Res 1994; 35(2): 135-40.
  38. North K and Golding J: A maternal vegetarian diet in pregnancy is associated with hypospadias. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. BJU Int 2000; 85(1): 107-13.
  39. Fort P, Moses N, Fasano M, Goldberg T and Lifshitz F: Breast and soy-formula feedings in early infancy and the prevalence of autoimmune thyroid disease in children. J Am Coll Nutr 1990; 9(2): 164-67.
  40. Suzuki A, Sugihara A, Uchida K, Sato T, Ohta Y, Katsu Y, Watanabe H and Iguchi T: Developmental effects of perinatal exposure to bisphenol-A and diethylstilbestrol on reproductive organs in female mice. Reprod Toxicol 2002; 16(2): 107-16.

**How to cite this article:**

Banik S, Banik AD and Shrivastava VK: Anovulatory follicle development in adult albino mice due to prolonged exposures to genistein. Int J Pharm Sci & Res 2014; 5(9): 3752-57. doi: 10.13040/IJPSR.0975-8232.5(9).3752-57.